The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Loss from operations | -12,081,066 | - |
| Sale of royalty and milestone rights, net | 0 | - |
| Interest expense | 615,754 | - |
| Interest income | -445,804 | - |
| Other income (expense), net | -293,460 | - |
| Net (loss) income | -3,562,766 | -8,394,790 |
| Depreciation and amortization | 481,906 | 618,185 |
| Deferred financing cost amortization | 124,251 | 11,622 |
| Right-of-use asset - operating lease | -130,958 | -251,291 |
| Accounts receivable | - | 0 |
| Stock-based compensation expense | 403,027 | 736,375 |
| Loss on disposal of property and equipment | 0 | 0 |
| Non-cash royalty revenue related to sale of future royalties | 202 | 4,255 |
| Non-cash interest expense | 62,306 | 125,387 |
| Other receivables | 181,041 | -41,866 |
| Prepaid expenses | -84,506 | -469,750 |
| Other current assets | 53,159 | - |
| Other non-current assets | 72,722 | -29,070 |
| Operating lease liability | -138,894 | -266,338 |
| Deposits | - | 0 |
| Accounts payable | 518,208 | -152,082 |
| Accrued expenses | -618,168 | -388,070 |
| Interest payable | 149,269 | 268,738 |
| Deferred grant funding | -2,230,386 | 4,234,748 |
| Net cash (used in) provided by operating activities | -442,135 | -10,887,999 |
| Purchases of property and equipment | 174,702 | 3,935 |
| Net cash used in investing activities | -174,702 | -3,935 |
| Net proceeds from issuance of common stock | 18,744,042 | 911,261 |
| Repayment of liability on sale of future royalties | 0 | 0 |
| Issuance of note payable | 486,720 | - |
| Payments on note payable | 121,680 | 249,628 |
| Principal payments on financing lease | 458,850 | 458,850 |
| Net cash provided by financing activities | 18,650,232 | 202,783 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 6,860 | 25,983 |
| Net change in cash, cash equivalents and restricted cash | 18,040,255 | -10,663,168 |
| Cash and cash equivalents at beginning of period | 15,998,174 | - |
| Cash and cash equivalents at end of period | 23,375,261 | - |
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)